MarketResearchNest.com adds “Chronic Urticaria Or Hives – Pipeline Review, H2 2017” new report to its research database. The report spread across in 51 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives – Pipeline Review, H2 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.
Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin’s surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=268799
The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 4 and 3 respectively.
Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
Biofrontera AG, ELORAC Inc, Faes Farma SA, Fountain Biopharma Inc, Genentech Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Mycenax Biotech Inc, Novartis AG, Synermore Biologics Co Ltd
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=268799
Featured News & Press Releases:
Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada
Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan
Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN
Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration
Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico
Jan 24, 2012: Faes Farma announces bilastine’s launch in Brazil
Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=268799
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain